TMEM25 is a candidate biomarker methylated and down-regulated in colorectal cancer

Disease Markers

Volumn 34, Issue 2, 2013, Pages 93-104

  Hrašovec, Sonja ^a   Hauptman, Nina ^a   Glavač, Damjan ^a   Jelenc, Franc ^b   Ravnik Glavač, Metka ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

array based methylation profiling; Colorectal cancer; DNA methylation; high resolution melting; TMEM25 down regulation; TMEM25 hypermethylation

Indexed keywords

BIOLOGICAL MARKER; MEMBRANE PROTEIN; MESSENGER RNA; TRANSMEMBRANE 25 PROTEIN; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CARCINOGENESIS; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENOME; GENOME ANALYSIS; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84873618918     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-120948     Document Type: Article

References (39)

1. D. Cunningham, W. Atkin, H.J. Lenz, H.T. Lynch, B. Minsky, B. Nordlinger and N. Starling, Colorectal cancer, Lancet 375 (2010), 1030-1047.
2. W.M. Grady and J.M. Carethers, Genomic and epigenetic instability in colorectal cancer pathogenesis, Gastroenterology 135 (2008), 1079-1099.
3. M. Esteller, Epigenetics in cancer, N Engl J Med 358 (2008), 1148-1159.
4. J. Sandoval and M. Esteller, Cancer epigenomics: beyond genomics, Curr Opin Genet Dev 22 (2012), 50-55.
5. M. Toyota, N. Ahuja, M. Ohe-Toyota, J.G. Herman, S.B. Baylin and J.P. Issa, CpG island methylator phenotype in colorectal cancer, Proc Natl Acad Sci USA 96 (1999), 8681-8686.
6. D.J. Weisenberger, K.D. Siegmund, M. Campan, J. Young, T.I. Long, M.A. Faasse, G.H. Kang, M. Widschwendter, D. Weener, D. Buchanan, H. Koh, L. Simms, M. Barker, B. Leggett, J. Levine, M. Kim, A.J. French, S.N. Thibodeau, J. Jass, R. Haile and P.W. Laird, CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer, Nat Genet 38 (2006), 787-793.
7. J.M. Teodoridis, C. Hardie and R. Brown, CpG island methylator phenotype (CIMP) in cancer: causes and implications, Cancer Lett 268 (2008), 177-186.
8. S. Lee, K.S. Hwang, H.J. Lee, J.S. Kim and G.H. Kang, Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia, Lab Invest 84 (2004), 884-893.
9. M.X. Draht, R.R. Riedl, H. Niessen, B. Carvalho, G.A. Meijer, J.G. Herman, E.M. van, V. Melotte and K.M. Smits, Promoter CpG island methylation markers in colorectal cancer: the road ahead, Epigenomics 4 (2012), 179-194.
10. J.M. Yi, M. Dhir, N.L. Van, S.R. Downing, J. Jeschke, S.C. Glockner, C.M. de Freitas, C.M. Hooker, J.M. Funes, C. Boshoff, K.M. Smits, E.M. van, M.P. Weijenberg, C.A. Iacobuzio-Donahue, J.G. Herman, K.E. Schuebel, S.B. Baylin and N. Ahuja, Genomic and epigenomic integration identifies a prognostic signature in colon cancer, Clin Cancer Res 17 (2011), 1535-1545.
11. A.A. Rawluszko, P. Krokowicz and P.P. Jagodzinski, Butyrate induces expression of 17beta-hydroxysteroid dehydrogenase type 1 in HT29 and SW707 colorectal cancer cells, DNA Cell Biol 30 (2011), 661-669.
12. Y. Kondo, Epigenetic cross-talk between DNA methylation and histone modifications In human cancers, Yonsei Med J 50 (2009), 455-463.
13. G. Berginc, M. Bracko, M. Ravnik-Glavač, D. Glavač, Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for population specific detection strategy of Lynch syndrome, Fam Cancer 8(4) 2009, 421-9.
14. J. Grimberg, S. Nawoschik, L. Belluscio, R.McKee, A. Turck and E. Einsenberg, A simple and efficient non-organic procedure for the isolation of genomic DNA from blood, Nucleic Acids Res 17(20) 1989, 8390.
15. C.L. Andersen, J.L. Jensen and T.F. Orntoft, Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets, Cancer Res 64 (2004), 5245-5250.
16. P. Doolan, M. Clynes, S. Kennedy, J.P. Mehta, S. Germano, C. Ehrhardt, J. Crown and L. O'Driscoll, TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer, Tumour Biol 30 (2009), 200-209.
17. T.D. Schmittgen and K.J. Livak, Analyzing real-time PCR data by the comparative C(T) method, Nat Protoc 3 (2008), 1101-1108.
18. M.G. Kibriya, M. Raza, F. Jasmine, S. Roy, R. Paul-Brutus, R. Rahaman, C. Dodsworth, M. Rakibuz-Zaman, M. Kamal and H. Ahsan, A genome-wide DNAmethylation study in colorectal carcinoma, BMC Med Genomics 4 (2011), 50.
19. B. Oster, K. Thorsen, P. Lamy, T.K. Wojdacz, L.L. Hansen, K. Birkenkamp-Demtroder, K.D. Sorensen, S. Laurberg, T.F. Orntoft and C.L. Andersen, Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas, Int J Cancer 129 (2011), 2855-2866.
20. Y.H. Kim, H.C. Lee, S.Y. Kim, Y.I. Yeom, K.J. Ryu, B.H. Min, D.H. Kim, H.J. Son, P.L. Rhee, J.J. Kim, J.C. Rhee, H.C. Kim, H.K. Chun, W.M. Grady and Y.S. Kim, Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations, Ann Surg Oncol 18 (2011), 2338-2347.
21. M. Bibikova, B. Barnes, C. Tsan, V. Ho, B. Klotzle, J.M. Le, D. Delano, L. Zhang, G.P. Schroth, K.L. Gunderson, J.B. Fan and R. Shen, High density DNA methylation array with single CpG site resolution, Genomics 98 (2011), 288-295.
22. T. Reinert, C. Modin, F.M. Castano, P. Lamy, T.K. Wojdacz, L.L. Hansen, C.Wiuf, M. Borre, L. Dyrskjot and T.F. Orntoft, Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers, Clin Cancer Res 17 (2011), 5582-5592.
23. M. Bibikova, J. Le, B. Barnes, S. Saedinia-Melnyk, L. Zhou, R. Shen and K.L. Gunderson, Genome-wide DNA methylation profiling using Infinium(R) assay, Epigenomics 1 (2009), 177-200.
24. J. Sandoval, H. Heyn, S. Moran, J. Serra-Musach, M.A. Pujana, M. Bibikova and M. Esteller, Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome, Epigenetics 6 (2011), 692-702.
25. J. Roessler, O. Ammerpohl, J. Gutwein, B. Hasemeier, S.L. Anwar, H.H. Kreipe and U. Lehmann, Quantitative crossvalidation and content analysis of the 450 k DNA methylation array from Illumina, Inc, BMC Res Notes 5 (2012), 210.
26. D. Wang, L. Yan, Q. Hu, L.E. Sucheston, M.J. Higgins, C.B. Ambrosone, C.S. Johnson, D.J. Smiraglia and S. Liu, IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data, Bioinformatics 28 (2012), 729-730.
27. S. Dedeurwaerder, M. Defrance, E. Calonne, H. Denis, C. Sotiriou and F. Fuks, Evaluation of the Infinium Methylation 450K technology, Epigenomics 3 (2011), 771-784.
28. C.D. Jee, M.A. Kim, E.J. Jung, J. Kim and W.H. Kim, Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma, Eur J Cancer 45 (2009), 1282-1293.
29. J. Tan, P.L. Lee, Z. Li, X. Jiang, Y.C. Lim, S.C. Hooi and Q. Yu, B55beta-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer, Cancer Cell 18 (2010), 459-471.
30. B.S. Gloss, K.I. Patterson, C.A. Barton, M. Gonzalez, J.P. Scurry, N.F. Hacker, R.L. Sutherland, P.M. O'Brien and S.J. Clark, Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers, Cancer Lett 318 (2012), 76-85.
31. M. Katoh and M. Katoh, Identification and characterization of human TMEM25 and mouse Tmem25 genes in silico, Oncol Rep 12 (2004), 429-433.
32. V. Kulasingam, M.P. Pavlou and E.P. Diamandis, Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer, Nat Rev Cancer 10 (2010), 371-378.
33. T.K. Wojdacz and A. Dobrovic, Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation, Nucleic Acids Res 35 (2007), e41.
34. T.K. Wojdacz, A. Dobrovic and L.L. Hansen, Methylationsensitive high-resolution melting, Nat Protoc 3 (2008), 1903-1908.
35. D.A. Heideman, I. Lurkin, M. Doeleman, E.F. Smit, H.M. Verheul, G.A. Meijer, P.J. Snijders, E.Thunnissen and E.C. Zwarthoff, KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA, J Mol Diagn 14 (2012), 247-255.
36. R. Amornpisutt, R. Sriraksa and T. Limpaiboon, Validation of methylation-sensitive high resolution melting for the detection of DNA methylation in cholangiocarcinoma, Clin Biochem (2012
37. C. Dahl and P. Guldberg, High-resolution melting for accurate assessment of DNA methylation, Clin Chem 53 (2007), 1877-1878.
38. S. Houshdaran, S. Hawley, C. Palmer, M. Campan, M.N. Olsen, A.P. Ventura, B.S. Knudsen, C.W. Drescher, N.D. Urban, P.O. Brown and P.W. Laird, DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines, PLoS One 5 (2010), e9359.
39. M.H. Saied, J. Marzec, S. Khalid, P. Smith, T.A. Down, V.K. Rakyan, G. Molloy, M. Raghavan, S. Debernardi and B.D. Young, Genome wide analysis of acute myeloid leukemia reveal leukemia specific methylome and subtype specific hypomethylation of repeats, PLoS One 7 (2012), e33213.